News for Eagle Pharmaceuticals Stock (EGRX)

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 02/03/24

SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 02/02/24

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)

PRNewsWire • 02/02/24

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 02/01/24

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 01/31/24

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 01/30/24

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

PRNewsWire • 01/30/24

EARLY FEBRUARY DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 01/29/24

ROSEN, A LEADING LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - EGRX

PRNewsWire • 01/26/24

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 01/26/24

EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options

PRNewsWire • 01/25/24

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 01/24/24

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 01/23/24

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 01/22/24

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

Accesswire • 01/19/24

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

GlobeNewsWire • 01/18/24

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

Accesswire • 01/17/24

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

Accesswire • 01/16/24

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors in Eagle Pharmaceuticals, Inc. - EGRX

PRNewsWire • 01/14/24

ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EGRX

PRNewsWire • 01/09/24

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

Accesswire • 01/08/24

ROSEN, A LONGSTANDING LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EGRX

PRNewsWire • 01/03/24

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGRX

Business Wire • 01/02/24

SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses to Contact the Firm

Accesswire • 01/02/24

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Eagle Pharmaceuticals, Inc. (EGRX) Investors and Encourages Investors to Contact the Firm Before February 9, 2024

Business Wire • 12/29/23